Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Issues
2019
December 2019, Vol 10, No 6
December 2019, Vol 10, No 6
Pemigatinib Effective in Patients with Cholangiocarcinoma and FGFR2 Fusion or Rearrangement
By
Wayne Kuznar
Cholangiocarcinoma
December 2019, Vol 10, No 6
Data from the single-arm, open-label phase 2 clinical trial FIGHT-202, which was presented at the ESMO Congress 2019, revealed that investigational pemigatinib induced a response in 35.5% of the 107 patients with
FGFR2
fusions or rearrangements (cohort A), with a median duration of response of 7.5 months.
Read Article
Practice-Changing Results: Ivosidenib First Targeted Therapy to Show Benefits in Patients with Cholangiocarcinoma and IDH1 Mutation
By
Wayne Kuznar
Cholangiocarcinoma
December 2019, Vol 10, No 6
Barcelona, Spain—Ivosidenib (Tibsovo), an oral therapy that targets isocitrate dehydrogenase-1 (
IDH1
) mutation, significantly improved progression-free survival (PFS) in patients with advanced cholangiocarcinoma (CCA) and an
IDH1
mutation, in a phase 3 clinical trial reported lead investigator Ghassan K. Abou-Alfa, MD, Medical Oncologist, Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center, New York City, at the ESMO Congress 2019.
Read Article
Medical Cannabis in Patients with Advanced Cancer: Many Challenges Remain
By
Corbin Davis
Medical Marijuana
,
Supportive Care 2019 Symposium
December 2019, Vol 10, No 6
San Francisco, CA—Cannabis has been credited as a medicinal plant with benefits ranging from pain and inflammation relief to epileptic seizure reduction to insomnia and anxiety cures, but the evidence is still limited, particularly in the setting of advanced cancer.
Read Article
Psychosocial Issues in Patients with Cancer: It’s Time for Real-World Interventions
By
Corbin Davis
Supportive Care 2019 Symposium
December 2019, Vol 10, No 6
San Francisco, CA—There is no shortage of research on psychosocial issues in patients with cancer, but implementation of this evidence in clinical practice has a long way to go, according to data presented at the 2019 Supportive Care in Oncology Symposium.
Read Article
Nivolumab plus Ipilimumab Combination Improves Survival in Patients with Metastatic NSCLC
Lung Cancer
,
Personalized Medicine
,
Solid Tumors
December 2019, Vol 10, No 6
Barcelona, Spain—The immunotherapy combination of nivolumab (Opdivo) plus ipilimumab (Yervoy) improved overall survival (OS) compared with chemotherapy as first-line treatment in patients with advanced non–small-cell lung cancer (NSCLC) and PD-L1 expression ≥1%, according to results of CheckMate 227.
Read Article
Osimertinib Superior TKI as First-Line Treatment of Advanced NSCLC with EGFR Mutation
By
Phoebe Starr
Lung Cancer
,
Personalized Medicine
,
Solid Tumors
December 2019, Vol 10, No 6
Barcelona, Spain—Osimertinib (Tagrisso), a third-generation EGFR tyrosine kinase inhibitor (TKI), extended overall survival (OS) compared with older TKI EGFR inhibitors, including gefitinib (Iressa) or erlotinib (Tarceva), as first-line treatment for patients with advanced non–small-cell lung cancer (NSCLC) and
EGFR
mutation in the phase 3 clinical trial called FLAURA.
Read Article
Zejula Receives FDA Approval for HRD-Positive Advanced Ovarian Cancer
FDA Approvals, News & Updates
December 2019, Vol 10, No 6
On October 23, 2019, the FDA approved a new indication for the PARP inhibitor niraparib (Zejula; Tesaro) for the treatment of patients with homologous recombination deficiency repair (HRD)-positive advanced ovarian, fallopian tube, or primary peritoneal cancer, after receiving ≥3 chemotherapy regimens.
Read Article
FDA Approves Calquence for Adults with CLL or SLL
FDA Approvals, News & Updates
December 2019, Vol 10, No 6
On November 21, 2019, the FDA accelerated the approval of acalabrutinib (Calquence; AstraZeneca) for adults with chronic lymphocytic leukemia (CLL) or with small lymphocytic lymphoma. This drug was approved 4 months earlier than the FDA PDUFA date.
Read Article
Tecentriq Approved with Chemotherapy for First-Line Treatment of Metastatic NSCLC without EGFR or ALK Mutations
FDA Approvals, News & Updates
December 2019, Vol 10, No 6
On December 3, 2019, the FDA approved atezolizumab (Tecentriq; Genentech), in combination with paclitaxel protein-bound (Abraxane) and carboplatin chemotherapy, for the first-line treatment of adults with metastatic nonsquamous non–small-cell lung cancer (NSCLC) that does not harbor EGFR or ALK genomic mutations.
Read Article
Ziextenzo Third Biosimilar to Neulasta Approved for Febrile Neutropenia
FDA Approvals, News & Updates
,
Biosimilars
December 2019, Vol 10, No 6
On November 5, 2019, the FDA approved pegfilgrastim-bmez (Ziextenzo; Sandoz) as a third biosimilar to Neulasta (pegfilgrastim), a granulocyte colony-stimulating factor. The previous 2 biosimilars to Neulasta were approved in 2018.
Read Article
Page 2 of 3
1
2
3
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Medication Assurance Programs, as Deceiving and Harmful as Alternate Funding Programs
Dawn Holcombe, MBA, FACMPE, ACHE
2.
Addressing Challenges to Adoption of Value-Based Agreements
Phoebe Starr
3.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma